Taxotere
(docetaxel)ApprovedSmall molecule
Docetaxel is a chemotherapy drug used to treat various types of cancer, including breast cancer, lung cancer, prostate cancer, and gastric cancer by slowing or stopping the growth of cancer cells.[2] Taxotere is currently approved and in use across 145 indications[4].[1]
Taxotere is one of 1327 small molecule programs targeting Ovarian Cancer. It is currently in Approved.
145
Indications
1,665
Total Trials
22
Active Trials
1,326
Competitors
11
FDA Applications
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 143 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Approved
Blenoxane
Bristol-Myers SquibbPreclinical
Spravato
WWim Janssens
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Tianeptine
PfizerPreclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer42 trials
A Study for the Adjuvant Treatment of Breast Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420467·2,413 enrolled
Show 39 more trials
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Completed·—·Phase 1·NCT00268918·24 enrolled
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Completed·NNanogen Pharmaceutical Biotechnology Joint Stock Company·Phase 3·NCT05301010·128 enrolled
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
Active, not recruiting·—·Phase 2·NCT00295893·121 enrolled
Non-Small Cell Lung Cancer37 trials
Show 34 more trials
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT00075374·6 enrolled
Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT00514293·39 enrolled
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT00660816·46 enrolled
Prostate Cancer20 trials
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
Completed·—·Phase 2·NCT00005096·19 enrolled
Show 17 more trials
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05189457·32 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03043807·26 enrolled
Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients
Terminated·—·Phase 2·NCT00714376·6 enrolled
Squamous Cell Carcinoma8 trials
Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Completed·—·Phase 1/2·NCT00139269·38 enrolled
Show 5 more trials
Gastric Cancer7 trials
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Completed·—·Phase 2·NCT00394433·38 enrolled
Show 4 more trials
59 more indications
Metastatic Prostate Cancer6 trials
Pancreatic Cancer4 trials
Show 1 more trial
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Completed·—·Phase 2·NCT00882310·37 enrolled
Advanced NSCLC3 trials
Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC
Unknown status·—·Phase 2·NCT03411967·20 enrolled
A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
Unknown status·—·Phase 2·NCT03732001·80 enrolled
Gastroesophageal Junction Cancer3 trials
Advanced Solid Tumors3 trials
Esophageal Cancer3 trials
Nasopharyngeal Carcinoma2 trials
Head and Neck Cancer2 trials
Small Cell Lung Cancer2 trials
Solid Tumors2 trials
Cervical Cancer2 trials
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
Unknown status·—·Phase 2/3·NCT04138992·150 enrolled
Fallopian Tube Cancer2 trials
Ovarian Cancer2 trials
Lung Cancer2 trials
Patients With Solid Tumors2 trials
Non-squamous NSCLC2 trials
Patients With Advanced Solid Tumors2 trials
Trial1 trial
Neoadjuvant Chemotherapy1 trial
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
Terminated·—·Phase 2·NCT05567835·3 enrolled
Epithelial Tumor1 trial
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
Completed·—·Phase 1·NCT00004082
Intraperitoneal1 trial
A Dose-finding Trial of Hyperthermic Intraperitoneal Docetaxel
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT05410483·30 enrolled
Solid Malignancies1 trial
Nivolumab1 trial
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Completed·—·Phase 2·NCT03894891·6 enrolled
Uterine Leiomyosarcoma1 trial
RAS Mutation1 trial
Cancer of the Head and Neck1 trial
Carcinoma1 trial
Oxaliplatin1 trial
Locally Advanced Head and Neck Cancer1 trial
Pathological Response1 trial
Newly Diagnosed1 trial
Paclitaxel1 trial
Lung Carcinoma1 trial
Locally Advanced1 trial
Esophageal Squamous Cell Carcinoma1 trial
Refractory Solid Tumors1 trial
Ovarian Carcinoma1 trial
Epstein Barr Virus1 trial
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
Completed·—·Phase 2·NCT00953420·20 enrolled
Adenocarcinoma1 trial
Metastatic NSCLC1 trial
Advanced Urothelial Cancer1 trial
Ovarian Epithelial Cancer1 trial
Cancer of Unknown Primary1 trial
Growth1 trial
Recurrent Head and Neck Cancer1 trial
Recurrent or Refractory Solid Tumors1 trial
Elderly Patients1 trial
Lung Squamous Cell Cancer1 trial
Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT01660399·300 enrolled
Objective Response Rate1 trial
Synovial Sarcoma1 trial
Regulatory
FDA Approval Timeline[5]
Aug 3, 2010
TAXOTERE
NDA NDA020449
Mar 8, 2011
DOCETAXEL
NDA NDA022234
May 3, 2011
DOCEFREZ
NDA NDA022534
Jun 8, 2011
DOCETAXEL
NDA NDA201195
Jun 29, 2011
DOCETAXEL
NDA NDA201525
Jan 11, 2012
DOCETAXEL
NDA NDA022312
Apr 12, 2013
DOCETAXEL
NDA NDA203551
Mar 13, 2014
DOCETAXEL
NDA NDA202356
Dec 22, 2015
DOCETAXEL
NDA NDA205934
Nov 22, 2022
DOCIVYX
NDA NDA215813
Oct 23, 2024
BEIZRAY
NDA NDA218711
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Taxotere drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for docetaxel. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]